The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...

Modern Family’ alum Eric Stonestreet opened up to PEOPLE about living with type 2 diabetes and being unable to get a grasp on ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

Eli Lilly LLY-5.46%decrease; red down pointing triangle revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio. The drug maker logged ...

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...

Eli Lilly and Company LLY reported first-quarter 2025 ... sales of Lilly’s popular tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. Total revenues beat the ...

Shares of Eli Lilly ( LLY -10.61%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Eli Lilly's weekly prescription data for Zepbound is up 354% year over year while Novo Nordisk's Wegovy is up just 61%.

Eli Lilly CEO Dave Ricks urged the Trump ... tariffs could have on American exporters like Eli Lilly. In an earnings call May 1, Ricks said leaders of the Indianapolis pharmaceutical company support ...